Evaluation of the Safety and Pharmacokinetics of Oleander 4X in Healthy Volunteers

A Phase 1, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of Oleander 4X in Healthy Volunteers

The homeopathic medicine, Oleander 4X HPUS is indicated for temporary relief of symptoms associated with flu, such as muscle or body aches, headaches, chills and fever, cough, and congestion. The primary purpose of this study is to assess the safety of Oleander 4X HPUS in health male and female subjects compared to a placebo. This is a randomized, double blind, placebo-controlled Phase I Proof of Concept clinical trial to evaluate the safety and efficacy of OLEANDER 4X HPUS in Healthy Volunteers. Briefly, 45 Healthy volunteers who meet the eligibility criteria and agree to participation in the study will be placed on 1.0 mL of OLEANDER 4X HPUS, four-to-twelve times per day for seven days. For the pharmacokinetics study (cohorts 4-6), participants will take OLEANDER 4X HPUS at a prescribed dose one time.

The aim of the present study is to evaluate the safety of OLEANDER 4X HPUS. This real-world cohort provides a unique opportunity to study this medicine. This protocol outlines a study involving Healthy volunteers. Up to 45 volunteers will be recruited in specific health systems in the USA.

Second ARM, sub-study: As a second arm of this study, a random double blind, placebo-controlled pharmacokinetics study in healthy volunteers. Briefly, 15 healthy volunteers who meet the same eligibility criteria and agree to participation in the study will be placed on one, two, or 4 doses (1 mL per dose) of OLEANDER 4X HPUS one time.

This is effectively three ascending doses in 4 subjects on OLEANDER 4X HPUS, compared to the placebo (1 subject).

Study Overview

• Status: Unknown
• Conditions: Flu-like Symptoms
• Intervention / Treatment: Drug: Oleander 4X - single; Drug: Oleander 4X - double; Drug: Oleander 4X - quadruple; Drug: Placebo

Detailed Description

The aim of the present study is to evaluate the safety of OLEANDER 4X HPUS. This protocol outlines a study involving Healthy volunteers. Up to 45 volunteers will be recruited in the USA.

Second ARM, sub-study: As a second arm of this study, a random double blind, placebo-controlled pharmacokinetics study in healthy volunteers. Briefly, 15 healthy volunteers who meet the same eligibility criteria and agree to participation in the study will be placed on one, two, or 4 doses (1 mL per dose) of OLEANDER 4X HPUS one time.

This is effectively three ascending doses in 4 subjects on OLEANDER 4X HPUS, compared to the placebo (1 subject).

• Study Type: Interventional
• Enrollment (Anticipated): 75
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Virginia
    • Roanoke, Virginia, United States, 24017
      • Recruiting
      • Dr. William Ball offices
      • Contact: William Ball, MD; Phone Number: 540-772-1006; Email: roanokefamilymed@gmail.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy Volunteers.
• Subjects with no symptoms of respiratory illness such as fever, rhinorrhea, mild cough, sore throat, headache, fatigue, muscle pain, and malaise but with no shortness of breath.
• Male or non-pregnant female adult > 18 to 65 years of age at time of enrollment to include all races and ethnic minorities.
• Agree to the collection of blood specimens (for the pharmacokinetics study).
• Willingness of study participant to provide informed consent and accept randomization to any assigned treatment arm.
• Must agree not to enroll in another study of an investigational agent prior to Day 28 of study, unless hospitalized.

Exclusion Criteria:

• Signs of any respiratory distress or pulmonary infection defined as the need for non-invasive or invasive mechanical ventilator support, ECMO or shock requiring vasopressor support.
• Subjects with risk factors for severe disease (e.g. hypertension, diabetes, pulmonary, cardiovascular, renal, hepatic, neurologic disease or immune compromise, obesity, and pregnancy).
• Any previous history of clinically significant cardiovascular disease, including ventricular arrhythmias.
• Current use of cardiac glycosides or a known allergic reaction to cardiac glycosides or compounds of similar chemical or biologic composition.
• Any risk factors that can lead to severe COVID-19 including uncontrolled diabetes, hypertension, and systemic diseases including hepatic disease and renal insufficiency.
• Pregnancy or breastfeeding.
• Participation in any other clinical trial of an experimental treatment for COVID-19.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Safety of Oleander 4X HPUS; : To evaluate the clinical safety of OLEANDER 4X HPUS in healthy volunteers relative to the control arm (placebo group).	Drug: Oleander 4X - single; Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.; Drug: Oleander 4X - double; Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.; Drug: Oleander 4X - quadruple; Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.; Drug: Placebo; The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days
Experimental: Pharmacokinetics evaluation of Oleander 4X HPUS; To evaluate the pharmacokinetics of OLEANDER 4X HPUS versus placebo.	Drug: Oleander 4X - single; Cohort 1 receive 4 doses of Oleander 4X in a 24-hour period for a period of seven days.; Drug: Oleander 4X - double; Cohort 2 receive 2 doses of either active drug or placebo 4 times per day in a 24-hour period for a period of seven days.; Drug: Oleander 4X - quadruple; Cohort 3 receive 4 doses of either active drug four times per day in a 24-hour period for a period of seven days.; Drug: Placebo; The placebo group receives 4 doses of placebo in a 24-hour period for a period of 7 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with adverse events, serious event, and any related reactions as assessed by CTCAE v5.0.		1-7 days
proportion of subjects undergoing DLT events	Safety evaluation	1-7 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
pharmacokinetic parameters - AreaUnderCUrve (AUCt) [Time Frame: 24 hours]	AUCt plasma concentration of oleander (using Oleandrin as the marker) during 24 hours after administration.	0-24 hours
half-life (t1/2)	half-life (t1/2) of oleander extract (using Oleandrin as the marker) during 24 hours after administration.	0-24 hours
maximum and minimum plasma concentration	maximum and minimum plasma concentration of oleander extract (using Oleandrin as the marker) during 24 hours after administration.	0-24 hours
total body clearance (Cltot)	total body clearance (Cltot) of oleander extract (using Oleandrin as the marker) during 24 hours after administration.	0-24 hours

Collaborators and Investigators

• Sponsor: Avila Herbals
• Investigators: Study Director: Theresa G Obiso, PhD, Avila Herbals

Study record dates

Study Major Dates

• Study Start (Actual): November 24, 2020
• Primary Completion (Anticipated): January 15, 2021
• Study Completion (Anticipated): January 15, 2021

Study Registration Dates

• First Submitted: November 23, 2020
• First Submitted That Met QC Criteria: December 14, 2020
• First Posted (Actual): December 19, 2020

Study Record Updates

• Last Update Posted (Actual): December 21, 2020
• Last Update Submitted That Met QC Criteria: December 17, 2020
• Last Verified: December 1, 2020

More Information

Terms related to this study

• Keywords: Flu-like symptoms; Avila Herbals; Phoenix Biotechnology
• Other Study ID Numbers: AH-O4X-11-2020-01

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No